ACRV — Acrivon Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1781174 ·
Last close
$2.06
Market Cap
$88.28M
52W High
$3.56
52W Low
$1.27
ADV30
359,886
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -18,668,000 | -17,964,000 | 99,092,000 | 41,417,000 | 12,427,000 |
| Mar 2026 | 0 | — | -19,902,000 | -19,042,000 | 107,832,000 | 34,064,000 | 12,317,000 |
| Dec 2025 | 0 | — | -20,116,000 | -18,985,000 | 129,717,000 | 41,499,000 | 17,201,000 |
| Sep 2025 | 0 | — | -19,687,000 | -18,234,000 | 145,299,000 | 35,405,000 | 16,696,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-64,668,000
Investing CF
$60,013,000
Financing CF
$-439,000
CapEx
$-1,625,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.02
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-293,923,000
Inventory
—
Receivables
—
ST Investments
$63,673,000
EBIT TTM
$-82,354,000
Pretax Income TTM
$-77,267,000
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -84,114,000 | -77,905,000 | 129,717,000 | 17,201,000 | 112,516,000 | -63,665,000 |
| Dec 2024 | 0 | -89,199,000 | -80,556,000 | 196,588,000 | 19,802,000 | 176,786,000 | -65,669,000 |
| Dec 2023 | 0 | -67,103,000 | -60,388,000 | 138,265,000 | 17,070,000 | 121,195,000 | -42,641,000 |
| Dec 2022 | 0 | -32,657,000 | -31,167,000 | 181,226,000 | 10,751,000 | 170,475,000 | -30,117,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.69
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PRNAF | ALTERITY THERAPEUTICS LTD | $87.40M | $0.40 | — |
| RANI | Rani Therapeutics Holdings, Inc. | $89.57M | $0.78 | — |
| RVRC | Revium Rx. | $86.84M | $1.43 | — |
| RLYB | Rallybio Corp | $90.54M | $17.05 | — |
| NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | $91.03M | $3.16 | — |
News headlines (Yahoo Finance, 1h cache)
What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock
2026-09-15 16:00 · Yahoo
Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?
2026-09-03 13:55 · Yahoo
Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference
2026-09-02 12:00 · Yahoo
Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer
2026-08-31 12:30 · Yahoo
Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy
2026-08-24 16:00 · Yahoo
Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference
2026-07-21 20:30 · Yahoo
Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit
2026-05-21 11:30 · Yahoo
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-05-15 20:00 · Yahoo
Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Develo
2026-04-17 20:00 · Yahoo
Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts
2026-08-12 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.